Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mira PharmaceuticalsMIRA +4.60%13 3-1 Month Momentum % is -4.92% as of Aug. 21, 2026. GuruFocus rates MIRA with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 1,022 Drug Manufacturers companies, Mira Pharmaceuticals ranks worse than 52.05% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-21), Mira Pharmaceuticals's 3-1 Month Momentum % is -4.92%.
The industry rank for Mira Pharmaceuticals's 3-1 Month Momentum % or its related term are showing as below:
MIRA's 3-1 Month Momentum % is ranked worse than 52.05% of 1022
companies
in the Drug Manufacturers industry
Industry Median: -4.385
vs MIRA: -4.92
Mira Pharmaceuticals (NAS:MIRA) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Mira Pharmaceuticals 3-1 Month Momentum % Related Terms
MIRA vs NSRX, SCLX, MDCX: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - General subindustry, Mira Pharmaceuticals's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mira Pharmaceuticals 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mira Pharmaceuticals's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Mira Pharmaceuticals's 3-1 Month Momentum % falls into.
Mira Pharmaceuticals (NAS:MIRA) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mira Pharmaceuticals (MIRA) has a 3-1 Month Momentum % of -4.92% as of Aug. 21, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Mira Pharmaceuticals and its competitors. According to the industry distribution chart, Mira Pharmaceuticals ranks #532 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 52.1%.
Is Mira Pharmaceuticals' 3-1 Month Momentum % too high?
Mira Pharmaceuticals' current 3-1 Month Momentum % is -4.92%. Based on the distribution chart, Mira Pharmaceuticals ranks #532 out of 1022 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Mira Pharmaceuticals has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Mira Pharmaceuticals' 3-1 Month Momentum % compare to NSRX and SCLX?
According to the Drug Manufacturers industry distribution chart, Mira Pharmaceuticals ranks #532 out of 1022 companies for 3-1 Month Momentum %. This places Mira Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Mira Pharmaceuticals and its competitors. Mira Pharmaceuticals's current 3-1 Month Momentum % is -4.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mira Pharmaceuticals stock overvalued right now?
Mira Pharmaceuticals (MIRA) has a current 3-1 Month Momentum % of -4.92%. The current 3-1 Month Momentum % is -4.92%. Mira Pharmaceuticals' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Mira Pharmaceuticals (MIRA), the current 3-1 Month Momentum % is -4.92% as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
13GF Score
Get the complete analysis for MIRA
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIRA has been successfully added to your 
